An hourpost-injection (p.i.), 87% of the total radioactivity in plasma originatedfrom intact [methylpiperazine-11C]brigatinib.Significant differences in tumor uptake were observed between theendogenously EML4–ALK mutated H2228 and the control xenograftA549. This evidence concerns the gene ALK and neoplasm.